Investment Intelligence. Reimagined.
Listing data synced 2026-04-16. This is the listing record date, separate from quote updates.
Loading SEC business and financials…
Loading views…
Loading your outlook…
Loading…
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization.
Excerpt from Item 1 — Business; filed 2026-02-25. May be shortened.
Source: SEC Company Facts. Checked 2026-10-16. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
Showing a previously fetched snapshot. A recent refresh has not completed.
Biotechnology · US-listed · 10 companies in the recorded group
Same-market companies with the same recorded industry role. Coverage is partial; this is not a full-industry ranking.
Values in USD
Market caps are estimates based on cached closing prices and disclosed share counts.